Fusion Polypeptide Antibiotic for Gram-Negative Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid increase in antibiotic-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa, necessitates the development of new treatment methods that are distinct from conventional antibiotics, as they pose a significant global health threat.
Innovation Solution
A novel polypeptide derived from a bacteriophage with endolysin activity, combined with Cecropin A, forms a fusion polypeptide that exhibits enhanced antibiotic effects against gram-negative bacteria, including Pseudomonas aeruginosa, and can be used in combination with other antibiotics like polymyxin-based drugs to reduce resistance and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat gram-negative bacteria, then bacterial growth is inhibited, but antibiotic resistance develops rapidly
Solution Approach 1:
The invention creates a fusion polypeptide that combines endolysin (which degrades peptidoglycan in bacterial cell walls) with Cecropin A (which disrupts bacterial outer membranes). This composite structure enables simultaneous attack on both the cell wall and outer membrane of gram-negative bacteria, achieving effective killing while reducing the development of resistance compared to conventional single-mechanism antibiotics
Solution Approach 2:
The fusion polypeptide divides the antibacterial function into two distinct segments: the endolysin portion that targets peptidoglycan and the Cecropin A portion that targets the outer membrane. This segmentation allows each domain to perform its specific function independently, creating a multi-modal approach that overcomes resistance mechanisms
2Reliability
If high concentrations of antibiotics are used to kill bacteria, then bacterial growth is suppressed, but toxicity to host cells increases
Solution Approach 1:
The fusion polypeptide changes the concentration parameter required for effective bacterial killing. By combining two mechanisms (peptidoglycan degradation and outer membrane disruption), the polypeptide achieves potent antibacterial activity at lower concentrations than conventional antibiotics, thereby reducing host cell toxicity while maintaining effective bacterial suppression
3Reliability
If endolysin alone is used against gram-negative bacteria, then cell wall degradation occurs, but the outer membrane prevents effective action
Solution Approach 1:
The Cecropin A domain of the fusion polypeptide performs a preliminary action by disrupting the outer membrane before the endolysin domain can access and degrade the peptidoglycan layer. This sequential action removes the barrier that would otherwise prevent endolysin from reaching its target, enabling effective cell wall degradation in gram-negative bacteria
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion polypeptide demonstrates superior antibiotic efficacy against gram-negative bacteria at lower concentrations, reducing the risk of resistance and minimizing toxicity, while providing a synergistic effect when combined with other antibiotics.
Implementation Method 1
destroy the cell wall of the host bacterium using endolysin, a protein of bacteriophage
Implementation Method 2
a fusion polypeptide comprising the polypeptide and Cecropin A
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are a novel polypeptide, a fusion polypeptide comprising the polypeptide, and a use thereof as an antibiotic. More specifically, provided are a novel polypeptide derived from a bacteriophage, a novel fusion polypeptide comprising cecropin A, and an antibiotic against Gram-negative bacteria comprising the polypeptide and/or the fusion polypeptide.